Skip to main content
Journal cover image

Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States.

Publication ,  Journal Article
Stinis, CT; Abbas, AE; Teirstein, P; Makkar, RR; Chung, CJ; Iyer, V; Généreux, P; Kipperman, RM; Harrison, JK; Hughes, GC; Lyons, JM; Kar, B ...
Published in: JACC Cardiovasc Interv
April 22, 2024

BACKGROUND: The fifth-generation SAPIEN 3 Ultra Resilia valve (S3UR) incorporates several design changes as compared with its predecessors, the SAPIEN 3 (S3) and SAPIEN 3 Ultra (S3U) valves, including bovine leaflets treated with a novel process intended to reduce structural valve deterioration via calcification, as well as a taller external skirt on the 29-mm valve size to reduce paravalvular leak (PVL). The clinical performance of S3UR compared with S3 and S3U in a large patient population has not been previously reported. OBJECTIVES: The aim of this study was to compare S3UR to S3/S3U for procedural, in-hospital, and 30-day clinical and echocardiographic outcomes after transcatheter aortic valve replacement (TAVR). METHODS: Patients enrolled in the STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) Registry between January 1, 2021, and June 30, 2023, who underwent TAVR with S3UR or S3U/S3 valve platforms were propensity-matched and evaluated for procedural, in-hospital, and 30-day clinical and echocardiographic outcomes. RESULTS: 10,314 S3UR patients were propensity matched with 10,314 patients among 150,539 S3U/S3 patients. At 30 days, there were no statistically significant differences in death, stroke, or bleeding, but a numerically higher hospital readmission rate in the S3UR cohort (8.5% vs 7.7%; P = 0.04). At discharge, S3UR patients exhibited significantly lower mean gradients (9.2 ± 4.6 mm Hg vs 12.0 ± 5.7 mm Hg; P < 0.0001) and larger aortic valve area (2.1 ± 0.7 cm2 vs 1.9 ± 0.6 cm2; P < 0.0001) than patients treated with S3/S3U. The 29-mm valve size exhibited significant reduction in mild PVL (5.3% vs 9.4%; P < 0.0001). CONCLUSIONS: S3UR TAVR is associated with lower mean gradients and lower rates of PVL than earlier generations of balloon expandable transcatheter heart valve platforms.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

April 22, 2024

Volume

17

Issue

8

Start / End Page

1032 / 1044

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Recovery of Function
  • Prosthesis Design
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stinis, C. T., Abbas, A. E., Teirstein, P., Makkar, R. R., Chung, C. J., Iyer, V., … McCabe, J. M. (2024). Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States. JACC Cardiovasc Interv, 17(8), 1032–1044. https://doi.org/10.1016/j.jcin.2024.02.015
Stinis, Curtiss T., Amr E. Abbas, Paul Teirstein, Raj R. Makkar, Christine J. Chung, Vijay Iyer, Philippe Généreux, et al. “Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States.JACC Cardiovasc Interv 17, no. 8 (April 22, 2024): 1032–44. https://doi.org/10.1016/j.jcin.2024.02.015.
Stinis CT, Abbas AE, Teirstein P, Makkar RR, Chung CJ, Iyer V, et al. Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States. JACC Cardiovasc Interv. 2024 Apr 22;17(8):1032–44.
Stinis, Curtiss T., et al. “Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States.JACC Cardiovasc Interv, vol. 17, no. 8, Apr. 2024, pp. 1032–44. Pubmed, doi:10.1016/j.jcin.2024.02.015.
Stinis CT, Abbas AE, Teirstein P, Makkar RR, Chung CJ, Iyer V, Généreux P, Kipperman RM, Harrison JK, Hughes GC, Lyons JM, Rahman A, Kakouros N, Walker J, Roberts DK, Huang P-H, Kar B, Dhoble A, Logsdon DP, Khanna PK, Aragon J, McCabe JM. Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United States. JACC Cardiovasc Interv. 2024 Apr 22;17(8):1032–1044.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

April 22, 2024

Volume

17

Issue

8

Start / End Page

1032 / 1044

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Recovery of Function
  • Prosthesis Design